These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23046818)

  • 1. The impact of a disease management program (COACH) on the attainment of better cardiovascular risk control in dyslipidaemic patients at primary care centres (The DISSEMINATE Study): a randomised controlled trial.
    Selvaraj FJ; Mohamed M; Omar K; Nanthan S; Kusiar Z; Subramaniam SY; Ali N; Karanakaran K; Ahmad F; Low WH;
    BMC Fam Pract; 2012 Oct; 13():97. PubMed ID: 23046818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study.
    Andersson C; Lyass A; Vasan RS; Massaro JM; D'Agostino RB; Robins SJ
    Am Heart J; 2014 Dec; 168(6):878-83.e1. PubMed ID: 25458651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of an intervention to improve the cardiovascular health of family members of patients with coronary artery disease: a randomized trial.
    Reid RD; McDonnell LA; Riley DL; Mark AE; Mosca L; Beaton L; Papadakis S; Blanchard CM; Mochari-Greenberger H; O'Farrell P; Wells GA; Slovinec D'Angelo ME; Pipe AL
    CMAJ; 2014 Jan; 186(1):23-30. PubMed ID: 24246588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Financial Incentives to Physicians, Patients, or Both on Lipid Levels: A Randomized Clinical Trial.
    Asch DA; Troxel AB; Stewart WF; Sequist TD; Jones JB; Hirsch AG; Hoffer K; Zhu J; Wang W; Hodlofski A; Frasch AB; Weiner MG; Finnerty DD; Rosenthal MB; Gangemi K; Volpp KG
    JAMA; 2015 Nov; 314(18):1926-35. PubMed ID: 26547464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
    Colhoun HM; Leiter LA; Müller-Wieland D; Cariou B; Ray KK; Tinahones FJ; Domenger C; Letierce A; Israel M; Samuel R; Del Prato S
    Cardiovasc Diabetol; 2020 Feb; 19(1):14. PubMed ID: 32035487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of a programme of therapeutic exercise on different clinical indicators related to dyslipidaemia in adult subjects aged between 26 to 73 years with a cardiovascular risk factor].
    Meseguer Zafra M; Rosa Guillamón A; García-Cantó E; Rodríguez García PL; Pérez-Soto JJ; Tárraga López PJ; Del Moral García JE; Tárraga Marcos ML
    Hipertens Riesgo Vasc; 2019; 36(1):21-27. PubMed ID: 29636229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.
    Hovingh GK; Kastelein JJ; van Deventer SJ; Round P; Ford J; Saleheen D; Rader DJ; Brewer HB; Barter PJ
    Lancet; 2015 Aug; 386(9992):452-60. PubMed ID: 26047975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial.
    Ihm SH; Chung WB; Lee JM; Hwang BH; Yoo KD; Her SH; Song WH; Chae IH; Park TH; Kim JH; Jeon DW; Cho BR; Kang SH; Park SD; Lee JB; Woo JT; Lee BW; Han KA; Won KH; Kim HS; Yu JM; Chung CH; Kim HJ; Cho HC; Seung KB
    Clin Ther; 2020 Oct; 42(10):2021-2035.e3. PubMed ID: 32891418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lifestyle intervention on cardiometabolic risk factors: results of the POWER-UP trial.
    Vetter ML; Wadden TA; Chittams J; Diewald LK; Panigrahi E; Volger S; Sarwer DB; Moore RH;
    Int J Obes (Lond); 2013 Aug; 37 Suppl 1(0 1):S19-24. PubMed ID: 23921777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
    Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of computer-generated personalized goals on cholesterol lowering.
    Levetan CS; Dawn KR; Murray JF; Popma JJ; Ratner RE; Robbins DC
    Value Health; 2005; 8(6):639-46. PubMed ID: 16283864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of cardiovascular events in patients at optimal values for combined lipid parameters.
    Stanek EJ; Sarawate C; Willey VJ; Charland SL; Cziraky MJ
    Curr Med Res Opin; 2007 Mar; 23(3):553-63. PubMed ID: 17357251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five year trends in dyslipidaemia prevalence and management in Switzerland: the CoLaus study.
    Antiochos P; Marques-Vidal P; Waeber G; Vollenweider P
    Nutr Metab Cardiovasc Dis; 2015 Nov; 25(11):1007-15. PubMed ID: 26321470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of Korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg.
    Lee CW; Baek SH; Hong TJ; Choi YJ; Kim YJ; Ahn TH; Ihm SH; Bae JH; Hong SJ; Kim DI; Ahn YK; Hur SH; Park DG; Choi DJ; Lee SU; Kim BS; Ryu KH; Jang YS; Lee SH; Seung KB; Kim HS
    Cardiovasc Drugs Ther; 2010 Apr; 24(2):181-8. PubMed ID: 20383571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial.
    Aberg JA; Sponseller CA; Ward DJ; Kryzhanovski VA; Campbell SE; Thompson MA
    Lancet HIV; 2017 Jul; 4(7):e284-e294. PubMed ID: 28416195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bread enriched with phytosterols with or without curcumin modulates lipoprotein profiles in hypercholesterolaemic individuals. A randomised controlled trial.
    Ferguson JJA; Wolska A; Remaley AT; Stojanovski E; MacDonald-Wicks L; Garg ML
    Food Funct; 2019 May; 10(5):2515-2527. PubMed ID: 30990213
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.